ASML’s July 15 Crosshairs: Net Orders and the 100-System Hurdle Take Center Stage

ASML's Q2 results on July 15 hinge on 2027 EUV delivery targets. Analyst threshold of 90-100 tools could trigger revaluation amid chip-sector volatility and geopolitical risks.

When ASML reports second-quarter results on 15 July, the market will be looking past the headline numbers toward a single, decisive metric: the confirmed delivery roadmap for Extreme Ultraviolet (EUV) systems in 2027. Analysts at Morgan Stanley have drawn a line in the sand at 90 to 100 EUV tools — a threshold that, if hit, could unlock a revaluation of the Dutch lithography giant’s stock.

The shares have spent the past week in a state of nervous equilibrium. On Friday, ASML closed at €1,576.80, down from €1,585 on Thursday, stretching a seven-session decline to 3.14 per cent. Over the past year, however, the stock has still surged 129.32 per cent, a rally that few see as exhausted despite the recent pullback.

That pullback was not born from company-specific news. A broad chip-sector sell-off ignited after Samsung Electronics published preliminary results for the second quarter — profits that, while high, fell short of already lofty expectations. The reaction ricocheted through Asian tech exchanges, triggering margin calls and trading halts in South Korea, and then swept across European chip-equipment makers, ASML included. The stock lost more than 5 per cent intraday on 9 July before recovering to close up 4.21 per cent.

The rebound gained momentum from two forces. Major memory-chip manufacturers swiftly announced massive capital expenditure plans directed at ASML systems through 2027 — Micron targeting $27 billion for fiscal 2026, and Samsung plus SK Hynix collectively outlining outlays of roughly $520 billion over multiple years. At the same time, analysts at Bernstein and Morgan Stanley raised their price targets, citing an unprecedented wave of artificial-intelligence-driven demand. Bernstein’s David Dai lifted his target from $1,971 to $2,623, projecting EUX deliveries of 91 systems in 2027 and 113 in 2028.

That bull case rests on ASML’s near-total dominance: a monopoly in EUV lithography and an estimated 98.5 per cent market share in immersion lithography. The next-generation High-NA EUV tools, priced at roughly €350 million each, are expected to become a major revenue engine, with analysts forecasting compound annual growth of 30 per cent in EUV-related sales to €42.7 billion by 2030.

Yet the stock carries a valuation that leaves little room for disappointment. At a price-to-earnings multiple of roughly 64.71, ASML commands a premium that demands flawless execution. The most immediate risk is geopolitical: export controls on chipmaking equipment continue to tighten. The Dutch government is moving closer to the US-led Pax Silica alliance, with regulators pressing to expand restrictions beyond EUV scanners to include older DUV tools and maintenance contracts for installed equipment in China. Nearly 20 per cent of ASML’s planned system revenues from China hang in the balance.

Customer behaviour adds another layer of uncertainty. Leading foundries, including TSMC, have reportedly delayed the adoption of ASML’s High-NA EUV platform, preferring cheaper packaging alternatives to expensive tool upgrades. Any sign that the adoption curve is flattening could weigh heavily on future order expectations.

Against this backdrop, the second-quarter report on 15 July becomes a fulcrum. JPMorgan expects revenue of €8.7 billion — a 13.1 per cent year-on-year advance — and earnings per share of €6.67, with a gross margin near 51.7 per cent. The net order intake, however, will be scrutinised more closely than any of these figures. A clear signal that net bookings support the 90-to-100 EUV system range for 2027 would allow the stock to sustain its momentum and potentially test the upper analyst targets between $2,300 and $2,623.

The alternative scenario is equally clear: stagnant net orders or cautious language from management on capacity expansion for 2027 would trigger a consolidation. The stock currently sits 9.79 per cent below its 52-week high of €1,748 and 6.69 per cent above its 50-day moving average of €1,477.88, leaving limited room for error. The relative strength index at 51.2 confirms a market that is neither overbought nor oversold — a tense equilibrium that the 15 July report is poised to break one way or another.